Clinical trial register · China

Clinical Trials in Nanyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC

19224

Studies in scope

all four open statuses

11811

Recruiting now

open to new participants

2030

Lead sponsors

across recruiting studies

Top sites

Beijing 5586 Shanghai 3885 Guangzhou 3356 Hangzhou 1825 Wuhan 1342

Trials with a site in Nanyang

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Not yet open

A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)

NCT07812597Obesity

DrugsZovaglutide·Semaglutide

Beijing QL Biopharmaceutical Co.,Ltd

Phase 2

210

Beijing, Huizhou, Handan, Langfang, Harbin, Nanyang, Yichang, Changde

2026-10-12

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

NCT07664553Type 2 Diabetes Mellitus

DrugElecoglipron

AstraZeneca

Phase 3

600

Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang

2026-07-08

Recruiting

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

NCT07662213Type 2 Diabetes Mellitus

DrugsElecoglipron·Semaglutide

AstraZeneca

Phase 3

1,200

Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang

2026-07-06

Recruiting

A Prospective, Multicenter, Randomized Controlled Trial Investigating the Impact of Fasting Duration on Postoperative Rebleeding Following Esophageal Variceal Ligation.

NCT07774143Esophageal Varices

The First Affiliated Hospital of Zhengzhou University

Not applicable

339

Anyang, Jiaozuo, Kaifeng, Luohe, Luoyang, Nanyang, Sanmenxia, Shangqiu

2026-06-20

Recruiting

A Study of TAK-755 in Adults With Acute Ischemic Stroke

NCT07392450Acute Ischemic Stroke

DrugTAK-755

Takeda

Phase 2

222

Beijing, Nanyang, Xuzhou, Jinan, Liaocheng, Linyi, Datong, Linfen

2026-05-17

By invitation

Large-scale Models of Esophageal Cancer and Related Research

NCT07642401Esophageal Cancer

The First Affiliated Hospital of Henan University of Science and Technology

Observational

12,000

Anyang, Luoyang, Nanyang

2026-05-15

Recruiting

Medeliver Intracranial Drug Coated Balloon Catheter for Symptomatic Intracranial Atherosclerotic Stenosis

NCT07542938Symptomatic Intracranial Atherosclerotic Stenosis

Xuanwu Hospital, Beijing

Not applicable

264

Beijing, Fuzhou, Shijiazhuang, Harbin, Nanyang, Zhengzhou, Baotou, Xi'an

2026-04-15

Recruiting

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT07291076Hepatocellular Carcinoma (HCC)

DrugsPumitamig·Yervoy·Ipilimumab

Bristol-Myers Squibb

Phase 1/2

198

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Nanyang

2026-03-16

Recruiting

A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.

NCT07658534Respiratory Syncytial Virus Infections

Shanghai Ark Biopharmaceutical Co., Ltd.

Phase 2/3

290

Beijing, Guangzhou, Cangzhou, Nanyang, Zhengzhou, Wuhan, Hangzhou, Rui’an

2026-03-03

Not yet open

A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis

NCT07432854Moderate to Severe Plaque Psoriasis

DrugCMS-D001

Dermavon Holdings Limited

Phase 2/3

540

Bengbu, Wuhu, Guangzhou, Chengde, Handan, Shijiazhuang, Harbin, Nanyang

2026-03-03

Active, closed

RBD5044 in Chinese Participants With Hypertriglyceridemia

NCT07587788Hypertriglyceridemia

DrugRBD5044

Ribotek Biopharmaceuticals (Shandong) Co., Ltd

Phase 2

Daqing, Harbin, Luoyang, Jingzhou, Nanyang, Yuncheng, Beijing

2026-02-28

Recruiting

A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms

NCT07228312Intracranial Aneurysm

Johnson & Johnson Medical (Shanghai) Ltd.

Observational

200

Chenzhou, Guangzhou, Nanjing, Nanyang, Taiyuan, Wuhu, Zhengzhou

2026-01-28

Recruiting

A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.

NCT07520565AIS

Biocells (Beijing) Biotech Co.,Ltd

Phase 3

1,112

Hengshui, Daqing, Nanyang, Meihekou, Shenyang, Xianyang, Linyi, Linfen

2026-01-19

Recruiting

A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors

NCT07321574SCLC, Extensive Stage, Advanced Solid Tumors

Shanghai AB PharmaTech Ltd.

Phase 2

110

Luoyang, Nanyang, Nanchang, Liaocheng, Shanghai, Taiyuan, Neijiang

2025-12-30

Not yet open

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

NCT07246317Breast Cancer

DrugsPertuzumab·Trastuzumab·Lenvatinib·Docetaxel

Tianjin Medical University Cancer Institute and Hospital

Phase 2

188

Guangzhou, Shijiazhuang, Luoyang, Nanyang, Chengdu, Tianjin, Jiaxing

2025-12-15

Recruiting

Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke

NCT07279493Acute Ischemic Stroke

Kunming Pharmaceuticals, Inc.

Phase 2

300

Beijing, Shenzhen, Cangzhou, Hengshui, Daqing, Anyang, Nanyang, Xuzhou

2025-11-22

Recruiting

Real-world Study of Aflibercept 8 mg in nAMD

NCT07640997Neovascular Age-Related Macular Degeneration (nAMD)

DrugAflibercept

Peking University People's Hospital

Observational

300

Beijing, Fuzhou, Shenzhen, Zunyi, Harbin, Nanyang, Wuhan, Hohhot

2025-11-11

Recruiting

Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy

NCT07581210Acute Ischemic Stroke

Shanghai QuietD Biotechnology Co., Ltd.

Phase 2

120

Meizhou, Luoyang, Nanyang, Changchun, Meihekou, Benxi, Fuxin, Shengyang

2025-10-14

Not yet open

The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study

NCT07180459Carcinoma, Hepatocellular Carcinoma

DrugDonafenib

Xuhua Duan

Observational

118

Guiyang, Haikou, Kaifeng, Luohe, Luoyang, Nanyang, Shangqiu, Zhoukou

2025-10-10

Not yet open

Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment

NCT06773117Cough

Tasly Pharmaceutical Group Co., Ltd

Phase 3

360

Hefei, Chongqing, Guangzhou, Zunyi, Xingtai, Kaifeng, Nanyang, Sanmenxia

2025-09-01

Not yet open

Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency

NCT07126288Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD), Growth Hormone

Shenzhen Kexing Pharmaceutical Co., Ltd.

Phase 2/3

268

Xiamen, Nanyang, Xinxiang, Wuhan, Suzhou, Nanchang, Pingxiang, Changchun

2025-08-31

Active, closed

Real-World Effectiveness of Zamerovimab and Mazorelvimab and Vaccine for Rabies Grade III Exposure in Nanyang

NCT07624461Rabies Post-exposure Prophylaxis, Rabies

DrugRabies Vaccine

Synermore Biologics (Suzhou) Co., Ltd.

Observational

Nanyang

2025-06-06

Recruiting

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867Acute Ischemic Stroke

Corxel Pharmaceuticals

Phase 2/3

740

Baotou, Beijing, Changchun, Guangzhou, Harbin, Kaili, Linfen, Nanyang

2025-05-15

Recruiting

ICP-332 in Subjects With Non-segmental Vitiligo

NCT07047612Non Segmental Vitiligo

DrugICP-332

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2/3

603

Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Luoyang, Nanyang

2025-05-09

Not yet open

A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis

NCT06958861Acute Exacerbations of Bronchiectasis

Shanghai Huilun Pharmaceutical Co., Ltd.

Phase 2

180

Fuyang, Hefei, Fuzhou, Guangzhou, Shenzhen, Baise City, Shijiazhuang, Nanyang

2025-05

Recruiting

Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions

NCT07463664Chronic Total Occlusions of Coronary Arteries, Chronic Total Occlusion (CTO), Coronary Artery Disease (CAD)

The First Affiliated Hospital of Zhengzhou University

Not applicable

200

Beijing, Anyang, Jiaozuo, Jiyuan, Kaifeng, Luoyang, Nanyang, Pingdingshan

2025-04-28

Recruiting

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

NCT06880770Severe Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

288

Beijing, Guangzhou, Guiyang, Harbin, Luoyang, Nanyang, Zhuzhou, Baotou

2025-04-24

Recruiting

A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.

NCT06788431Atherosclerosis

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Early Phase 1

Nanyang, Shanghai

2025-03-10

Recruiting

Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT06754891Inflammatory Bowel Diseases

DrugTQH3906

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1

135

Bengbu, Wuwei, Guangzhou, Huizhou, Harbin, Luoyang, Nanyang, Zhengzhou

2025-01-28

Recruiting

Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)

NCT03547232Acute Pancreatitis, Complication, Mortality Rate, Organ Failure, Multiple

DrugIndomethacin

Peking Union Medical College Hospital

Phase 4

1,504

Beijing, Guiyang, Baoding, Harbin, Dengzhou, Nanyang, Huaian, Nantong

2024-12-01

Recruiting

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

NCT06390306Chronic Myeloid Leukemia

DrugsPonatinib·Olverembatinib·Azacitidine·Venetoclax

Peking University People's Hospital

Observational

Beijing, Chengdu, Guangdong, Kunming, Nanjing, Nanning, Nanyang, Ningbo

2024-07-01

Active, closed

Evolve China PMCF Study

NCT06368622Intracranial Aneurysm

Stryker Neurovascular

Observational

500

Beijing, Changchun, Fuzhou, Guangzhou, Kunming, Nanyang, Ningbo, Qingdao

2024-04-24

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

NCT06256588Neoplasms, Head and Neck

DrugDostarlimab

GlaxoSmithKline

Phase 3

864

Chongqing, Baoding, Nanyang, Beijing, Changsha, Changzhou, Chengdu, Dongguan

2024-03-21

Active, closed

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118Dermatitis Atopic

DrugsPimecrolimus·Amlitelimab·Tacrolimus

Sanofi

Phase 3

464

Changchun, Chongqing, Guangzhou, Hangzhou, Nanyang, Ningbo, Shanghai, Shenyang

2024-02-29

Recruiting

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

NCT06112704Advanced Solid Tumor

DrugRis-Rez

Hansoh BioMedical R&D Company

Phase 2

220

Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang

2024-02-06

Active, closed

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT06073821CLL

DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

652

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jieyang, Nanning, Nanyang

2023-11-11

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Beijing, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Nanyang, Wuhan, Changsha

2023-11-08

Active, closed

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06095115Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

684

Beijing, Bengbu, Chengde, Chengdu, Jiaxing, Jinan, Nanchang, Nanyang

2023-10-12

Recruiting

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

NCT06141226Non-small-cell Lung Cancer

DrugsBenmelstobart·Anlotinib·Docetaxel

Tianjin Medical University Cancer Institute and Hospital

Phase 2

148

Huizhou, Nanyang, Lianyungang, Weihai, Tianjin

2023-04-12

Active, closed

SeQuent ® Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis

NCT06047964Stroke, Intracranial Atherosclerotic Stenosis

B. Braun Medical International Trading Company Ltd.

Not applicable

281

Beijing, Harbin, Nanyang, Changchun, Jining, Qingdao, Shanghai, Taiyuan

2023-03-23

Active, closed

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303Atherosclerotic Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

7,297

Beijing, Guangzhou, Huizhou, Nanning, Daqing, Harbin, Nanyang, Wuhan

2022-12-14

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shenzhen, Zhongshan, Nanyang

2022-09-13

Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

146

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Nanyang

2022-05-06

Active, closed

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis

DrugLuspatercept

Celgene

Phase 3

313

Guangzhou, Nanyang, Changsha, Nanjing, Nantong, Nanchang, Qingdao, Taiyuan

2021-02-25

Recruiting

Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

NCT04937283Lung Adenocarcinoma

Shanghai Pulmonary Hospital, Shanghai, China

Not applicable

690

Hefei, Nanyang, Nantong, Xuzhou, Yancheng, Jinan, Shanghai, Hangzhou

2019-10-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/city/nanyang

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 45 of those studies with a site in Nanyang.

How many clinical trials are recruiting in Nanyang?

26 of the 45 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 7 have not yet opened recruitment, 11 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanyang), 45 studies
Phase	Studies	Recruiting	Share
Phase 3	12	5	26.7%
Phase 2	10	6	22.2%
Observational	7	3	15.6%
Phase 2/3	6	3	13.3%
Not applicable	5	4	11.1%
Phase 1/2	2	2	4.4%
Early Phase 1	1	1	2.2%
Phase 1	1	1	2.2%
Phase 4	1	1	2.2%

Most active sponsors

Lead sponsors with the most studies (Nanyang)
Lead sponsor	Studies	Recruiting
AstraZeneca	2	2
BeOne Medicines	2	1
Peking University People's Hospital	2	2
The First Affiliated Hospital of Zhengzhou University	2	2
Tianjin Medical University Cancer Institute and Hospital	2	1
Amgen	1	0
Arrowhead Pharmaceuticals	1	1
B. Braun Medical International Trading Company Ltd.	1	0
Beijing InnoCare Pharma Tech Co., Ltd.	1	1
Beijing QL Biopharmaceutical Co.,Ltd	1	0

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.